Efficacy and Safety of Bosutinib Versus Imatinib in US Patients with Newly Diagnosed Chronic Myeloid Leukemia after 5-Years Follow-up in the Bfore Trial

Efficacy and Safety of Bosutinib Versus Imatinib in US Patients with Newly Diagnosed Chronic Myeloid Leukemia after 5-Years Follow-up in the Bfore Trial

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blood 2022-11, Vol.140 (Supplement 1), p.6798-6799
Hauptverfasser: Kota, Vamsi K., Deininger, Michael W., Mendler, Jason H., Shen, Wei, Goldman, Erinn Hoag, Cortes, Jorge E.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 6799
container_issue Supplement 1
container_start_page 6798
container_title Blood
container_volume 140
creator Kota, Vamsi K.
Deininger, Michael W.
Mendler, Jason H.
Shen, Wei
Goldman, Erinn Hoag
Cortes, Jorge E.
description
doi_str_mv 10.1182/blood-2022-162428
format Article
fullrecord <record><control><sourceid>elsevier_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1182_blood_2022_162428</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0006497122045815</els_id><sourcerecordid>S0006497122045815</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1378-423651cbfca594f5b2f43198265846f28e94defa56991c715d61836842d400ad3</originalsourceid><addsrcrecordid>eNp9kMtKAzEYhYMoWC8P4O5_gWiSSaYZXGm1KtQLeAFXQ5r8sdHpRJKpZd7Ex7W1rl0dzuI7HD5Cjjg75lyLk2kTo6OCCUF5KaTQW2TAldCUMcG2yYAxVlJZDfku2cv5nTEuC6EG5PvS-2CN7cG0Dh6Nx66H6OE85kUX2jCFF0x5keFmbjY9tPD8CA-rhm2XYRm6GdzhsunhIpi3NmZ0MJql2AYLtz02MTiY4OID58GA8R0mUPQVTcowjk0Tl3TxuR7tZgjnPiaEpxRMc0B2vGkyHv7lPnkeXz6Nrunk_upmdDahlhdDTaUoSsXt1FujKunVVHhZ8EqLUmlZeqGxkg69UWVVcTvkypVcF6WWwknGjCv2Cd_s2hRzTujrzxTmJvU1Z_Vabf2rtl6rrTdqV8zphsHVsa-Aqc52ZcOiCwltV7sY_qF_ANg1gfM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Efficacy and Safety of Bosutinib Versus Imatinib in US Patients with Newly Diagnosed Chronic Myeloid Leukemia after 5-Years Follow-up in the Bfore Trial</title><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Kota, Vamsi K. ; Deininger, Michael W. ; Mendler, Jason H. ; Shen, Wei ; Goldman, Erinn Hoag ; Cortes, Jorge E.</creator><creatorcontrib>Kota, Vamsi K. ; Deininger, Michael W. ; Mendler, Jason H. ; Shen, Wei ; Goldman, Erinn Hoag ; Cortes, Jorge E.</creatorcontrib><identifier>ISSN: 0006-4971</identifier><identifier>EISSN: 1528-0020</identifier><identifier>DOI: 10.1182/blood-2022-162428</identifier><language>eng</language><publisher>Elsevier Inc</publisher><ispartof>Blood, 2022-11, Vol.140 (Supplement 1), p.6798-6799</ispartof><rights>2022 The American Society of Hematology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Kota, Vamsi K.</creatorcontrib><creatorcontrib>Deininger, Michael W.</creatorcontrib><creatorcontrib>Mendler, Jason H.</creatorcontrib><creatorcontrib>Shen, Wei</creatorcontrib><creatorcontrib>Goldman, Erinn Hoag</creatorcontrib><creatorcontrib>Cortes, Jorge E.</creatorcontrib><title>Efficacy and Safety of Bosutinib Versus Imatinib in US Patients with Newly Diagnosed Chronic Myeloid Leukemia after 5-Years Follow-up in the Bfore Trial</title><title>Blood</title><issn>0006-4971</issn><issn>1528-0020</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9kMtKAzEYhYMoWC8P4O5_gWiSSaYZXGm1KtQLeAFXQ5r8sdHpRJKpZd7Ex7W1rl0dzuI7HD5Cjjg75lyLk2kTo6OCCUF5KaTQW2TAldCUMcG2yYAxVlJZDfku2cv5nTEuC6EG5PvS-2CN7cG0Dh6Nx66H6OE85kUX2jCFF0x5keFmbjY9tPD8CA-rhm2XYRm6GdzhsunhIpi3NmZ0MJql2AYLtz02MTiY4OID58GA8R0mUPQVTcowjk0Tl3TxuR7tZgjnPiaEpxRMc0B2vGkyHv7lPnkeXz6Nrunk_upmdDahlhdDTaUoSsXt1FujKunVVHhZ8EqLUmlZeqGxkg69UWVVcTvkypVcF6WWwknGjCv2Cd_s2hRzTujrzxTmJvU1Z_Vabf2rtl6rrTdqV8zphsHVsa-Aqc52ZcOiCwltV7sY_qF_ANg1gfM</recordid><startdate>20221115</startdate><enddate>20221115</enddate><creator>Kota, Vamsi K.</creator><creator>Deininger, Michael W.</creator><creator>Mendler, Jason H.</creator><creator>Shen, Wei</creator><creator>Goldman, Erinn Hoag</creator><creator>Cortes, Jorge E.</creator><general>Elsevier Inc</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20221115</creationdate><title>Efficacy and Safety of Bosutinib Versus Imatinib in US Patients with Newly Diagnosed Chronic Myeloid Leukemia after 5-Years Follow-up in the Bfore Trial</title><author>Kota, Vamsi K. ; Deininger, Michael W. ; Mendler, Jason H. ; Shen, Wei ; Goldman, Erinn Hoag ; Cortes, Jorge E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1378-423651cbfca594f5b2f43198265846f28e94defa56991c715d61836842d400ad3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kota, Vamsi K.</creatorcontrib><creatorcontrib>Deininger, Michael W.</creatorcontrib><creatorcontrib>Mendler, Jason H.</creatorcontrib><creatorcontrib>Shen, Wei</creatorcontrib><creatorcontrib>Goldman, Erinn Hoag</creatorcontrib><creatorcontrib>Cortes, Jorge E.</creatorcontrib><collection>CrossRef</collection><jtitle>Blood</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kota, Vamsi K.</au><au>Deininger, Michael W.</au><au>Mendler, Jason H.</au><au>Shen, Wei</au><au>Goldman, Erinn Hoag</au><au>Cortes, Jorge E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy and Safety of Bosutinib Versus Imatinib in US Patients with Newly Diagnosed Chronic Myeloid Leukemia after 5-Years Follow-up in the Bfore Trial</atitle><jtitle>Blood</jtitle><date>2022-11-15</date><risdate>2022</risdate><volume>140</volume><issue>Supplement 1</issue><spage>6798</spage><epage>6799</epage><pages>6798-6799</pages><issn>0006-4971</issn><eissn>1528-0020</eissn><pub>Elsevier Inc</pub><doi>10.1182/blood-2022-162428</doi><tpages>2</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0006-4971
ispartof Blood, 2022-11, Vol.140 (Supplement 1), p.6798-6799
issn 0006-4971
1528-0020
language eng
recordid cdi_crossref_primary_10_1182_blood_2022_162428
source EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
title Efficacy and Safety of Bosutinib Versus Imatinib in US Patients with Newly Diagnosed Chronic Myeloid Leukemia after 5-Years Follow-up in the Bfore Trial
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T18%3A17%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20and%20Safety%20of%20Bosutinib%20Versus%20Imatinib%20in%20US%20Patients%20with%20Newly%20Diagnosed%20Chronic%20Myeloid%20Leukemia%20after%205-Years%20Follow-up%20in%20the%20Bfore%20Trial&rft.jtitle=Blood&rft.au=Kota,%20Vamsi%20K.&rft.date=2022-11-15&rft.volume=140&rft.issue=Supplement%201&rft.spage=6798&rft.epage=6799&rft.pages=6798-6799&rft.issn=0006-4971&rft.eissn=1528-0020&rft_id=info:doi/10.1182/blood-2022-162428&rft_dat=%3Celsevier_cross%3ES0006497122045815%3C/elsevier_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_els_id=S0006497122045815&rfr_iscdi=true